Benjamin Wigman

Title: Benjamin Wigman: Innovator in Macrocyclic Compounds

Introduction

Benjamin Wigman is a notable inventor based in Woodland Hills, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of macrocyclic compounds. His work focuses on innovative methods for treating various forms of cancer.

Latest Patents

Wigman holds a patent for "Macrocyclic compounds and methods of use." This patent provides compounds that are useful for the inhibition of KRAS mutations, including G12D, G12V, G12A, G12S, G13D, Q61H, Q61L, or G12C. The compounds are described by a general Formula I′, with specific variables defined within the patent. Additionally, the disclosure includes pharmaceutical compositions that incorporate these compounds, highlighting their potential applications in cancer treatment.

Career Highlights

Throughout his career, Benjamin Wigman has demonstrated a commitment to advancing medical science through innovative research. His patent reflects a deep understanding of molecular biology and the complexities of cancer treatment. Wigman's work is a testament to the importance of innovation in the pharmaceutical industry.

Collaborations

Wigman has collaborated with notable colleagues, including Ryan Paul Wurz and Andrew Smaligo. These partnerships have likely contributed to the successful development of his patented compounds and their applications in cancer therapy.

Conclusion

Benjamin Wigman's contributions to the field of macrocyclic compounds represent a significant advancement in cancer treatment. His innovative approach and collaborative efforts underscore the importance of research and development in the pharmaceutical industry.